Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomised controlled trials

Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomised controlled trials

Background<br/> Platelet dysfunction, including that caused by antiplatelet agents, increases the risk of peri-operative bleeding. The optimal management of patients with platelet dysfunction undergoing surgery is unclear. <br/><br/>Objectives<br/> To assess whether desmopres...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Desborough, M, Oakland, K, Crivellari, M, Doree, C, Estcourt, L, Stanworth, S
Natura:	Journal article
Pubblicazione:	Wiley 2017

Documenti analoghi

Desmopressin use for minimising perioperative blood transfusion
di: Desborough, M, et al.
Pubblicazione: (2017)

Desmopressin for treatment of thrombocytopenia or platelet dysfunction
di: Desborough, MJR
Pubblicazione: (2017)

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial
di: Desborough, M, et al.
Pubblicazione: (2019)

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial
di: Michael J R Desborough, et al.
Pubblicazione: (2020-11-01)

Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
di: Estcourt, L, et al.
Pubblicazione: (2015)

Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia (Protocol)
di: Estcourt, L, et al.
Pubblicazione: (2015)

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review
di: Desborough, M, et al.
Pubblicazione: (2016)

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review
di: Desborough, M, et al.
Pubblicazione: (2016)

Alternatives to allogeneic platelet transfusion
di: Desborough, M, et al.
Pubblicazione: (2016)

Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation
di: Desborough, M, et al.
Pubblicazione: (2016)

Red cell transfusions for prevention of bleeding: a systematic review and meta-analysis of randomized controlled trials
di: Desborough, M, et al.
Pubblicazione: (2016)

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review (Russian translation of Cochrane plain language summary)
di: Desborough, MJR, et al.
Pubblicazione: (2021)

Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation
di: Estcourt, L, et al.
Pubblicazione: (2017)

Is there a role for Desmopressin as an alternative to platelet transfusion prior to procedures or Radiological InterVEntions in thrombocytopenic critically ill patients (DRIVE)? Results of a randomised double-blind placebo-controlled feasibility trial
di: Desborough, M, et al.
Pubblicazione: (2022)

Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation (Protocol)
di: Estcourt, L, et al.
Pubblicazione: (2017)

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (Protocol).
di: Estcourt, L, et al.
Pubblicazione: (2014)

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (protocol)
di: Estcourt, L, et al.
Pubblicazione: (2014)

Pathogen-reduced platelets for the prevention of bleeding (protocol)
di: Butler, C, et al.
Pubblicazione: (2011)

Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia
di: Estcourt, L, et al.
Pubblicazione: (2016)

AntifibrinolyticAgents: Aprotinin, and Desmopressin
di: Pramila Bajaj
Pubblicazione: (2009-01-01)

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
di: Estcourt, L, et al.
Pubblicazione: (2016)

Pathogen-reduced platelets for the prevention of bleeding (Review)
di: Estcourt, L, et al.
Pubblicazione: (2017)

Pathogen-reduced platelets for the prevention of bleeding.
di: Butler, C, et al.
Pubblicazione: (2013)

Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation (Review)
di: Estcourt, L, et al.
Pubblicazione: (2015)

Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial
di: Desborough, MJR, et al.
Pubblicazione: (2024)

Pathogen-reduced platelets for the prevention of bleeding (Review)
di: Butler, C, et al.
Pubblicazione: (2013)

Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction
di: Estcourt, L, et al.
Pubblicazione: (2016)

Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia (Protocol)
di: Estcourt, L, et al.
Pubblicazione: (2015)

Prophylactic platelet transfusions
di: Estcourt, L, et al.
Pubblicazione: (2010)

Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial
di: Michael J. R. Desborough, et al.
Pubblicazione: (2024-08-01)

Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
di: Estcourt, L, et al.
Pubblicazione: (2012)

Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation
di: Estcourt, L, et al.
Pubblicazione: (2014)

Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction
di: Estcourt, L, et al.
Pubblicazione: (2015)

Antiplatelet Agents Inhibit The Generation Of Platelet-Derived Microparticles
di: Alice Giacomazzi, et al.
Pubblicazione: (2016-09-01)

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
di: Estcourt, L, et al.
Pubblicazione: (2015)

Different platelet count thresholds to guide use of prophylactic platelet transfusions for patients with hematological disorders after myelosuppressive chemotherapy or stem cell transplantation
di: Estcourt, L, et al.
Pubblicazione: (2016)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
di: Crighton, GL, et al.
Pubblicazione: (2015)

Platelet transfusions for patients with haematological malignancies: who needs them?
di: Estcourt, L, et al.
Pubblicazione: (2011)

Antiplatelet agents for the treatment of adults with COVID-19
di: Fischer, A-L, et al.
Pubblicazione: (2023)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
di: Alexander P. Bye, et al.
Pubblicazione: (2022-12-01)